Advertisement
ABBV or AMGN or MRK
Which Stock Would AI Choose? AbbVie (ABBV) vs. Amgen (AMGN) vs. Merck (MRK) Stock Comparison
Key Takeaways
- AbbVie (ABBV) has successfully transitioned beyond its Humira patent cliff, with Skyrizi and Rinvoq now annualizing at nearly $26 billion combined and driving robust revenue growth.
- Amgen (AMGN) offers a diversified biologics portfolio and an emerging obesity pipeline, but faces mixed analyst sentiment and an ongoing IRS dispute that adds uncertainty to its outlook.
- Merck (MRK) continues to generate enormous cash flow from its dominant KEYTRUDA franchise, though GARDASIL headwinds in China and the approaching KEYTRUDA loss of exclusivity (LOE) weigh on sentiment.
- ABBV has demonstrated the strongest recent momentum, with shares outperforming both AMGN and MRK in recent months, supported by beat-and-raise quarterly results and multiple regulatory catalysts.
- MRK trades at the lowest forward price-to-earnings (P/E) multiple of the three, reflecting market concerns about its post-KEYTRUDA growth trajectory despite a deep pipeline.
- All three companies maintain strong dividend profiles, but their growth narratives diverge significantly — favoring different investor priorities around near-term momentum, pipeline potential, and valuation.
Introduction
AbbVie (ABBV), Amgen (AMGN), and Merck (MRK) represent three of the most closely watched names in the global pharmaceutical and biotechnology sector. Together they account for over $850 billion in combined market capitalization and serve as bellwethers for industry trends ranging from immunology and oncology innovation to biosimilar competition and pricing policy. This comparison is particularly relevant for investors seeking exposure to large-cap healthcare with different growth profiles, risk factors, and valuation characteristics. Whether evaluating dividend reliability, pipeline depth, or relative performance, understanding how these three industry leaders stack up against one another can help frame informed portfolio decisions in today's evolving market environment.
ABBV Overview and Recent Performance
AbbVie, headquartered in North Chicago, Illinois, is a research-based biopharmaceutical company with leadership positions across immunology, neuroscience, oncology, and aesthetics. The company has executed one of the pharmaceutical industry's most successful patent-cliff transitions, replacing declining Humira revenues — which once accounted for more than half of total sales — with its next-generation immunology therapies Skyrizi and Rinvoq. In recent quarters, Skyrizi has annualized at approximately $18 billion in sales, while Rinvoq has surpassed an $8 billion annualized run rate, driven by expanding indications in inflammatory bowel disease, dermatology, and rheumatology. AbbVie's neuroscience portfolio, anchored by Vraylar, Botox Therapeutic, and the migraine drugs Ubrelvy and Qulipta, has also delivered strong double-digit growth in recent periods. The company has raised its full-year earnings guidance multiple times, reflecting confidence in sustained momentum. Additionally, AbbVie has been active on the mergers and acquisitions (M&A) front, closing the acquisition of Capstan Therapeutics to bolster its immunology pipeline and entering the obesity space through a licensing agreement targeting long-acting amylin analogs. With no major LOE events expected for the remainder of the decade, AbbVie enjoys a multi-year runway for reinvestment and portfolio expansion.
AMGN Overview and Recent Performance
Amgen, based in Thousand Oaks, California, is one of the world's largest independent biotechnology companies, with a commercial portfolio spanning oncology, cardiovascular disease, bone health, inflammation, and biosimilars. The company's recent growth has been supported by newer products including Repatha, TEZSPIRE, EVENITY, and its expanding biosimilars segment, which together have accounted for a growing share of quarterly sales. Amgen's pipeline has drawn considerable attention for MariTide, an investigational obesity candidate that could position the company in one of the most commercially significant therapeutic categories of the decade. However, Amgen's near-term narrative has been complicated by several factors. An ongoing IRS dispute covering tax years 2016 through 2018 has introduced financial uncertainty, while regulatory setbacks — including the European Medicines Agency's recommendation to revoke marketing authorization for Tavneos and the FDA's proposed U.S. withdrawal of the drug — have raised questions about portfolio risk management. In recent weeks, Amgen shares have shown relatively range-bound trading activity, reflecting a market that appears to be weighing the company's pipeline promise against nearer-term headwinds. Analyst consensus on AMGN currently skews toward a "Hold" rating, with a wide dispersion of price targets that underscores differing views on the stock's risk-reward balance.
MRK Overview and Recent Performance
Merck, headquartered in Rahway, New Jersey, is a global pharmaceutical leader with a dominant position in oncology, a substantial vaccines franchise, and a growing presence in cardiovascular and animal health. The company's flagship product, KEYTRUDA, remains one of the world's best-selling medicines, generating approximately $8 billion in quarterly revenue and continuing to grow through new indications and earlier-stage cancer settings. However, Merck's recent performance has been shaped by a dramatic 55% decline in GARDASIL sales, driven primarily by weakened demand and elevated channel inventories in China — a headwind that management expects to persist through at least the end of 2025. On the positive side, WINREVAIR, Merck's therapy for pulmonary arterial hypertension, has surpassed $1 billion in cumulative sales in just over a year since launch, and the company has announced a $10 billion acquisition of Verona Pharma to add Ohtuvayre, a first-in-class COPD treatment, to its portfolio. Merck has also launched a multiyear, $3 billion cost-optimization initiative aimed at redirecting resources toward higher-growth pipeline opportunities. The stock has underperformed peers in recent months, with shares reflecting investor caution around GARDASIL headwinds, the approaching KEYTRUDA LOE later this decade, and integration risk from the Verona Pharma transaction. Nonetheless, with over 80 Phase 3 programs underway and a non-GAAP gross margin above 82%, Merck retains significant financial firepower to navigate this transitional period.
Trending AI Robots
For traders and investors seeking an analytical edge in evaluating stocks like ABBV, AMGN, and MRK, Tickeron's Trending AI Robots page offers a curated selection of the platform's most capable AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that trade across thousands of different tickers, each employing distinct trading styles, strategies, and timeframes — from short-term swing trading to longer-duration trend following. Only the most statistically promising bots, those best aligned with current market conditions, earn a place in the Trending AI Robots section. Bots featured on this page vary in their historical performance statistics, with some demonstrating win rates above 70%, track records spanning multiple years, and specialized capabilities for trading pharmaceutical and biotechnology stocks. Each bot provides transparent metrics including the number of trades executed, average trade duration, and performance benchmarks. For those interested in exploring how artificial intelligence can complement traditional analysis in the biopharmaceutical sector, visiting the Trending AI Robots page may offer a useful starting point.
Head-to-Head Comparison
When comparing ABBV, AMGN, and MRK, several differentiating factors emerge. In terms of business model resilience, AbbVie stands out for having already navigated its most significant patent cliff and emerged with a clear growth trajectory powered by Skyrizi and Rinvoq, which enjoy protection through the early 2030s. Amgen faces ongoing erosion in its legacy portfolio — including Prolia, Enbrel, and Otezla — while its newer products are still scaling. Merck, meanwhile, faces the most consequential upcoming LOE event of the three, with KEYTRUDA's patent expiration in the late 2020s looming as a challenge the company is actively working to offset through pipeline expansion and business development.
On revenue growth momentum, AbbVie has delivered consistent mid-single-digit top-line expansion ex-Humira, with ex-Humira portfolio growth exceeding 22% in recent quarters. Merck's headline revenue has contracted modestly due to GARDASIL headwinds, though excluding that impact, underlying growth has been robust. Amgen has posted mid-single-digit revenue growth supported by biosimilars and newer products, though at a more modest pace than ABBV's immunology-driven trajectory.
From a valuation perspective, MRK trades at the lowest forward earnings multiple of the three, a reflection of market skepticism about its post-KEYTRUDA future. ABBV commands a moderate premium, supported by its clearer growth visibility, while AMGN's valuation sits between the two, tempered by mixed analyst sentiment. Dividend investors will note that all three companies have strong track records of returning capital to shareholders, with ABBV historically offering the highest yield among them. In terms of risk factors, MRK faces the most acute single-product concentration risk, AMGN contends with tax and regulatory overhangs, and ABBV must demonstrate that its aesthetics business can stabilize amid macroeconomic pressures on consumer spending.
Tickeron AI Verdict
Based on observable factors including trend consistency, earnings momentum, pipeline breadth, and relative positioning, Tickeron's AI analytical framework would likely favor AbbVie (ABBV) among these three stocks in the current market environment. ABBV has demonstrated the clearest upward trend trajectory in recent months, supported by consecutive beat-and-raise quarters, successful execution of its post-Humira strategy, and multiple regulatory catalysts that provide visible growth runways. While Amgen offers intriguing pipeline optionality through MariTide and Merck's valuation may appeal to deep-value investors, ABBV's combination of confirmed revenue growth, limited near-term LOE risk, and proactive business development activity presents what the AI would interpret as the most balanced risk-reward profile. As always, this assessment reflects probabilistic analysis rather than a definitive prediction, and relative positioning could shift as new data emerge across all three names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileAMGN’s FA Score has 4 green FA rating(s), and MRK’s FA Score reflects 2 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- AMGN’s FA Score: 4 green, 1 red.
- MRK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while AMGN’s TA Score has 6 bullish TA indicator(s), and MRK’s TA Score reflects 5 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 5 bearish.
- AMGN’s TA Score: 6 bullish, 3 bearish.
- MRK’s TA Score: 5 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.91% price change this week, while AMGN (@Pharmaceuticals: Major) price change was +2.66% , and MRK (@Pharmaceuticals: Major) price fluctuated +2.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.95%. For the same industry, the average monthly price growth was +1.76%, and the average quarterly price growth was +4.67%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 31, 2026.
AMGN is expected to report earnings on Aug 04, 2026.
MRK is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.95% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | AMGN | MRK | |
| Capitalization | 458B | 203B | 324B |
| EBITDA | 16.9B | 16.7B | 19.4B |
| Gain YTD | 16.194 | 16.558 | 26.345 |
| P/E Ratio | 127.14 | 26.17 | 36.92 |
| Revenue | 62.8B | 37.2B | 65.8B |
| Total Cash | N/A | 12B | N/A |
| Total Debt | 72.9B | 57.3B | 49.1B |
ABBV | AMGN | MRK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 94 | 50 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 10 Undervalued | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 5 | 18 | 42 | |
SMR RATING 1..100 | 1 | 12 | 47 | |
PRICE GROWTH RATING 1..100 | 7 | 21 | 8 | |
P/E GROWTH RATING 1..100 | 17 | 57 | 7 | |
SEASONALITY SCORE 1..100 | 28 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (10) in the Biotechnology industry is somewhat better than the same rating for ABBV (66) in the Pharmaceuticals Major industry, and is significantly better than the same rating for MRK (87) in the Pharmaceuticals Major industry. This means that AMGN's stock grew somewhat faster than ABBV’s and significantly faster than MRK’s over the last 12 months.
ABBV's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is in the same range as AMGN (18) in the Biotechnology industry, and is somewhat better than the same rating for MRK (42) in the Pharmaceuticals Major industry. This means that ABBV's stock grew similarly to AMGN’s and somewhat faster than MRK’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as AMGN (12) in the Biotechnology industry, and is somewhat better than the same rating for MRK (47) in the Pharmaceuticals Major industry. This means that ABBV's stock grew similarly to AMGN’s and somewhat faster than MRK’s over the last 12 months.
ABBV's Price Growth Rating (7) in the Pharmaceuticals Major industry is in the same range as MRK (8) in the Pharmaceuticals Major industry, and is in the same range as AMGN (21) in the Biotechnology industry. This means that ABBV's stock grew similarly to MRK’s and similarly to AMGN’s over the last 12 months.
MRK's P/E Growth Rating (7) in the Pharmaceuticals Major industry is in the same range as ABBV (17) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for AMGN (57) in the Biotechnology industry. This means that MRK's stock grew similarly to ABBV’s and somewhat faster than AMGN’s over the last 12 months.
| ABBV | AMGN | MRK | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 39% | 3 days ago 41% | 3 days ago 50% |
| Stochastic ODDS (%) | 3 days ago 46% | 3 days ago 55% | 3 days ago 52% |
| Momentum ODDS (%) | 3 days ago 64% | 3 days ago 61% | 3 days ago 59% |
| MACD ODDS (%) | 3 days ago 50% | 3 days ago 61% | 3 days ago 54% |
| TrendWeek ODDS (%) | 3 days ago 62% | 3 days ago 61% | 3 days ago 56% |
| TrendMonth ODDS (%) | 3 days ago 64% | 3 days ago 59% | 3 days ago 55% |
| Advances ODDS (%) | 3 days ago 59% | 3 days ago 59% | 3 days ago 55% |
| Declines ODDS (%) | 13 days ago 48% | 7 days ago 51% | 7 days ago 51% |
| BollingerBands ODDS (%) | 3 days ago 45% | 3 days ago 48% | 3 days ago 52% |
| Aroon ODDS (%) | 3 days ago 66% | 3 days ago 54% | 3 days ago 65% |
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.95% | ||
| BMY - ABBV | 52% Loosely correlated | +0.94% | ||
| NVS - ABBV | 50% Loosely correlated | -0.72% | ||
| AMGN - ABBV | 46% Loosely correlated | +1.22% | ||
| MRK - ABBV | 45% Loosely correlated | +0.45% | ||
| JNJ - ABBV | 42% Loosely correlated | +1.59% | ||
More | ||||
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | +1.22% | ||
| BIIB - AMGN | 62% Loosely correlated | +0.78% | ||
| PFE - AMGN | 52% Loosely correlated | -0.16% | ||
| GILD - AMGN | 52% Loosely correlated | -1.18% | ||
| MRK - AMGN | 50% Loosely correlated | +0.45% | ||
| ABBV - AMGN | 47% Loosely correlated | +0.95% | ||
More | ||||
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.